pregabalin NDC 14445-173

NDC codes

FDA NDC Directory

Product NDC (as listed)14445-173Labeler and product segments. Claims need a package NDC.

Product NDC at billing width14445-0173Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
14445-173-90	14445017390	90 CAPSULE in 1 BOTTLE (14445-173-90)Marketed from May 17, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): pregabalin
Generic name (nonproprietary): pregabalin
Active ingredients: Pregabalin — 25 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Indoco Remedies Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 208113
Marketing start: May 17, 2024
Listing expires: Dec 31, 2026
DEA schedule: CV
Identifiers: Product ID 14445-173_522b3d6c-10fb-4581-afb7-2e48150b6048SPL ID 522b3d6c-10fb-4581-afb7-2e48150b6048SPL set ID 0a8d9e35-46fd-4c70-bb7f-4e8b754f2794RxCUI 483438, 483440, 483442, 483444, 483446, 483448, 483450, 577127UNII 55JG375S6M

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N414445017390 followed by a unit qualifier and the quantity

Package 14445-0173-90. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 25, 2025.

Indications (excerpt from the label)

Pregabalin capsules are indicated for: • Management of neuropathic pain associated with diabetic peripheral neuropathy • Management of postherpetic neuralgia • Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older • Management of fibromyalgia • Management of neuropathic pain associated with spinal cord injury Pregabalin capsules are indicated for: • Neuropathic pain associated with diabetic peripheral neuropathy (DPN) ( 1 ) • Postherpetic neuralgia (PHN) ( 1 ) • Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older ( 1 ) • Fibromyalgia ( 1 ) • Neuropathic pain associated with spinal cord injury ( 1 )…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 208113

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 208113
Product	Strength	Form · route	Labeler	Product NDC
pregabalin	Pregabalin 75 mg/1	CapsuleOral	Indoco Remedies Limited	14445-123
pregabalin	Pregabalin 150 mg/1	CapsuleOral	Indoco Remedies Limited	14445-125
pregabalin	Pregabalin 100 mg/1	CapsuleOral	Indoco Remedies Limited	14445-124
pregabalin	Pregabalin 200 mg/1	CapsuleOral	Indoco Remedies Limited	14445-126
pregabalin	Pregabalin 225 mg/1	CapsuleOral	Indoco Remedies Limited	14445-127
pregabalin	Pregabalin 300 mg/1	CapsuleOral	Indoco Remedies Limited	14445-128
pregabalin	Pregabalin 50 mg/1	CapsuleOral	Indoco Remedies Limited	14445-174